The potentials of MS‐based subproteomic approaches in medical science: The case of lysosomes and breast cancer
Authors: Journet Agnès , Ferro Myriam 
Published: March 2004

Abstract

I.
Introduction
00

II.
Functions and Biogenesis of the Lysosome
00

III.
Lysosomes and Breast Cancer
00

A.  Lysosomal Hydrolases
00

1.  Roles of the Lysosomal Enzymes in the Development of Breast Cancer
00

a.  ECM Degradation
00

b.  Angiogenesis
00

c.  Cell Proliferation and Apoptosis: Specific Roles of CatD
00

d.  Lysosomal Hydrolases at the Site of Metastasis
00

2.  Modifications of the Expression, Targeting, and Glycosylation Processing of Lysosomal Enzymes
00

a.  Overexpression of Lysosomal Hydrolases
00

b.  Altered Trafficking of Lysosomal Hydrolases
00

c.  Mannose‐6‐Phosphorylation
00

3.  Lysosomal Enzymes as Breast Cancer Biomarkers
00

a.  The Aspartic Protease, CatD
00

b.  The Cysteine Proteases, CatB and CatL
00

c.  Other Lysosomal Soluble Proteins
00

B.  M6P/IGFIIR and Breast Cancer
00

1.  M6P/IGFIIR Involvment in Cancer: Clinical and Experimental Evidence
00

2.  Biological and Physiological Mechanisms That Lead to Tumor Progression and Metastasis, Related to M6P/IGFIIR
00

C.  Lysosomal Membrane Proteins
00

1.  LAMP‐1 and LAMP‐2
00

2.  The Tetraspanin, CD63
00

D.  Conclusions
00

IV.
Subproteomics: The Example of the Lysosome, Phagolysosome, and Lysosome‐Related Organelles
00

A.  Fractionation and Starting Material
00

B.  Analytical Strategies to Identify Proteins From Lysosomes and Lysosome‐Related Organelles
00

C.  Checking the Localization of Lysosomal Proteins
00

D.  How to Decipher the Function of Lysosomal Proteins?
00

V.
Lysosomes and Breast Cancer: What are the Challenges for MS‐Based Proteomic Approaches?
00

A.  Starting Material: The Breast Cancer Cells
00

1.  Cell Lines Versus Tumor Samples: General Statements
00

2.  The Use of Breast Cancer Cells to Study the Lysosome or Lysosome‐Related Compartment
00

a.  Breast Cancer Cell Lines
00

b.  Microdissected cells
00

B.  MS‐Based Methods for a Better Understanding of Lysosomes in the Context of Breast Cancer
00

1.  How to Quantitate the Differential Expression of Lysosomal Proteins in the Case of Breast Cancer?
00

2.  PTMs of Lysosomal Proteins: How Can They be Monitored?
00

3.  Identification of Membrane Proteins to Study Breast Cancer
00

VI.
Conclusions
00

Acknowledgments
00

Abbreviations
00

References
00

Because of the great number of women who are diagnosed with breast cancer each year, and though this disease presents the lowest mortality rate among cancers, breast cancer remains a major public health problem. As for any cancer, the tumorigenic and metastatic processes are still hardly understood, and the biochemical markers that allow either a precise monitoring of the disease or the classification of the numerous forms of breast cancer remain too scarce. Therefore, great hopes are put on the development of high‐throughput genomic and proteomic technologies. Such comprehensive techniques should help in understanding the processes and in defining steps of the disease by depicting specific genes or protein profiles. Because techniques dedicated to the current proteomic challenges are continuously improving, the probability of the discovery of new potential protein biomarkers is rapidly increasing. In addition, the identification of such markers should be eased by lowering the sample complexity; e.g., by sample fractionation, either according to specific physico‐chemical properties of the proteins, or by focusing on definite subcellular compartments. In particular, proteins of the lysosomal compartment have been shown to be prone to alterations in their localization, expression, or post‐translational modifications (PTMs) during the cancer process. Some of them, such as the aspartic protease cathepsin D (CatD), have even been proven as participating actively in the disease progression. The present review aims at giving an overview of the implication of the lysosome in breast cancer, and at showing how subproteomics and the constantly refining MS‐based proteomic techniques may help in making breast cancer research progress, and thus, hopefully, in improving disease treatment. © 2004 Wiley Periodicals, Inc., Mass Spec Rev